Serum levels of tumour necrosis factor-α and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate - Preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy

European Journal of Cancer Care

Volumn 17, Issue 5, 2008, Pages 454-462

  Grim Stieger, M ^a   Keilani, M ^a   Mader, R M ^a   Marosi, C ^a   Schmidinger, M ^a   Zielinski, C C ^a   Fialka Moser, V ^a   Crevenna, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced cancer; Cytokines; IL 6; Palliative chemotherapy; Survival rate; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AMBULATORY CARE; APPETITE; ARTICLE; BLOOD; BODY MASS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; PALLIATIVE THERAPY; SURVIVAL RATE; WEIGHT REDUCTION;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; APPETITE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 50249143490     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00874.x     Document Type: Article

References (50)

1. Aleman M.R., Santolaria F., Batista N., de la Vega M.J., Gonzalez-Reimers E., Llanos A.M. Gomez-Sirvent J.L. (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19, 21 26.
2. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Christophoridou A.V., Perisinakis K., Hatzivasili A., Founoulakis A. Castanas E. (2004) Serum levels of Interleukin-6 in Multiple Myeloma patients and its relationship to disease activity. American Journal of Hematology 75, 101 106.
3. Ashizawa T., Okada R., Suzuki Y., Takagi M., Yamazaki T., Sumi T., Aoki T., Ohnuma S. Aoki T. (2005) Clinical significance of interleukine-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8, 124 131.
4. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A. Blay J.Y. (2003) Prognostic value of serum levels of interleukin-6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British Journal of Cancer 88, 1721 1726.
5. Balkwill F., Burke F., Talbot D., Tavernier J., Osborne R., Maylor S., Durbin H. Fiers W. (1987) Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2, 1229 1232.
6. Belluco C., Nitti D., Frantz M., Toppan P., Basso D., Plebani M., Lise M. Jessup J.M. (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Annals of Surgical Oncology 7, 133 138.
7. Berberoglu U., Yildirim E. Celen O. (2004) Serum levels of tumor necrosis factor-α correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. International Journal of Biological Markers 19, 130 134.
8. Berenstein E.G. Ortiz Z. (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD004310. doi: 10.1002/14651858.CD004310.pub2.
9. Bossola M., Muscaritoli M., Bellantone R., Pacelli F., Cascino A., Sagadri A., Battaglia F., Piccipni E., Scambia G., Doglietto G.B. Rossi Fanelli F. (2000) Serum tumor necrosis factor-α levels in cancer patients are discontinuous and correlate with weight loss. European Journal of Clinical Investigation 30, 1107 1112.
10. Bruera E. Sweeney C. (2000) Cachexia and asthenia in cancer patients. Lancet Oncology 1, 138 147.
11. Chung Y.C. Chang Y.F. (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. Journal of Surgical Oncology 83, 222 226.
12. Cohen T., Nahari D., Cerem L.W., Neufeld G. Levi B.Z. (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. Journal of Biological Chemistry 271, 736 741.
13. Crossley K.M., Bennell K.L., Cowan S.M. Green S. (2004) Analysis of outcome measures for persons with patellofemoral pain: which are reliable and valid? Archieves of Physical Medicine and Rehabilitation 85, 815 822.
14. Fearon K.C.H. Moses A.G.W. (2002) Cancer cachexia. International Journal of Cardiology 85, 73 81.
15. Gagnon B. Bruera E. (1998) A review of the drug treatment of cachexia associated with cancer. Drugs 55, 675 688.
16. Inui A. (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA: A Cancer Journal for Clinicians 52, 72 91.
17. Jatoi A., Egner J., Loprinzi C.L., Sloan J.A., Novotny P.J., Dakhil S.R., Mailliard J.A., Klee G.G. Krook J.E. (2004) Investigating the utility of serum cytokine measurements in a multiinstitutional cancer anorexia/weight loss trial. Supportive Care and Cancer 12, 604 644.
18. Kabir S., Grant C. Daar A.S. (1995) Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-α in patients with gastric carcinoma. Cancer Letters 95, 207 212.
19. Karnofsky D.A., Abelmann W.H., Craver L.F. Burchenal J.H. (1948) The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1, 634 656.
20. Madhusudan S., Protheroe A., Propper D., Han C., Corrie P., Earl H., Hancock B., Vasey P., Turner A., Balkwill F., Hoare S. Harris A.L. (2003) A multicenter phase II trial of bryostatin-1 in patients with advanced renal cancer. British Journal of Cancer 89, 1418 1422.
21. Mantovani G., Maccio A., Mura L., Massa E., Mudu M.C., Mulas C., Lusso M.R., Madeddu C. Dessi A. (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. Journal of Molecular Medicine 78, 554 561.
22. Mantovani G., Maccio A., Massa E. Madeddu C. (2001a) Managing cancer-related anorexia/cachexia. Drugs 61, 499 514.
23. Mantovani G., Maccio A., Madeddu C., Mura L., Massa E., Mudu M.C., Mulas C., Lusso M.R., Gramignano G. Piras M.B. (2001b) Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. Journal of Molecular Medicine 79, 406 414.
24. Mantovani G., Maccio A., Madeddu C., Mura L., Gramignano G., Lusso M.R., Mulas C., Mudu M.C., Murgia V., Camboni P., Massa E., Ferreli L., Contu P., Rinaldi A., Sanjust E., Atzei D. Elsener B. (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. International Journal of Cancer 98, 84 91.
25. Mantovani G., Maccio A., Madeddu C., Mura L., Gramignano G., Lusso M.R., Massa E., Mocci M. Serpe R. (2003a) Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. Journal of Molecular Medicine 81, 664 673.
26. Mantovani G., Madeddu C., Gramignano G., Lusso M.R., Mocci M., Massa E., Lerelli L., Astara G., Maccio A. Serpe R. (2003b) Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of live, and laboratory parameters. Journal of Experimental Therapeutics and Oncology 3, 205 219.
27. Mantovani G., Maccio A., Madeddu C., Mura L., Gramignano G., Lusso M.R., Murgia V., Camboni P., Ferreli L., Mocci M. Massa E. (2003c) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radical Research 37, 213 223.
28. Mantovani G., Madeddu C., Gramignano G., Ferelli L., Massa E., Contu P. Serpe R. (2004) Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients. Oncology Reports 11, 197 206.
29. Natali P., Nicotra M.R., Cavaliere R., Bigotti A., Romano G., Temponi M. Ferrone S. (1990) Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Research 50, 1271 1278.
30. Negrier S., Perol D., Menetrier-Caux C., Escudier B., Pallardy M., Ravaud A., Douillard J.Y., Chevreau C., Lasset C. Blay J.Y. (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the group francais d'immunotherapie. Journal of Clinical Oncology 22, 2371 2378.
31. Nikiteas N.I., Tzanakis N., Gazouli M., Rallis G., Daniilidis K., Theodoropoulos G., Kostakis A. Peros G. (2005) Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World Journal of Gastroenterology 11, 1639 1643.
32. Oliff A., Defo-Jones D., Boyer M., Martinez D., Kiefer D., Vuocolo G., Wolfe A. Socher S.H. (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555 563.
33. Parker B.A., Sturm K., MacIntosh C.G., Feinle C., Horowitz M. Chapman I.M. (2004) Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. European Journal of Clinical Nutrition 58, 212 218.
34. Parkin D., Rice N., Jacoby A. Doughty J. (2004) Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life. Social Science and Medicine 59, 351 360.
35. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace D. Corey E. (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211 1216.
36. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., Valero V., Arun B., Ibrahim N., Rivera E., Royce M., Cleeland C.S. Hortobagyi G.N. (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25, 94 102.
37. Rapellino M., Pecchio F., Aimo G., Priolo G., Baldi S., Ruffini E. Cianci R. (1992) Clinical significance of tumor necrosis factor in patients with bronchogenic carcinoma and benign lung diseases: a comparative study. International Journal of Biological Markers 7, 103 106.
38. Salgado R., Benoy I., Weytjens R., Van Bockstaele D., Van Marck E., Huget P., Hoylaerts M., Vermeulen P. Dirix L.Y. (2002) Arterio-venous gradients of IL-6, plasma and serum VEGF and d-dimers in human cancer. British Journal of Cancer 87, 1437 1444.
39. Salgado R., Junius S., Benoy I., Van Dam P., Vermeulen P., Van Marck E., Huget P. Dirix L.Y. (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer 103, 642 646.
40. Santini D., Fratto M.E., Vincenzi B., La Cesa A., Dianzani C. Tonini G. (2004) Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. Biodrugs 18, 269 278.
41. Sharma R. Anker S.D. (2002) Cytokines, apoptosis and cachexia: the potential for TNF antagonism. International Journal of Cardiology 85, 161 171.
42. Songur N., Kuru B., Kalkan F., Ozdilekcan C., Cakmak H. Hizel N. (2004) Serum interleukin-6 levels correlate with mal nutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90, 196 200.
43. Strassmann G., Fong M., Kenney J.S. Jacob C.O. (1992) Evidence for the involvement of interleukin-6 in experimental cancer cachexia. Journal of Clinical Investigation 89, 1681 1684.
44. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P. Boulamatsis D. (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. British Journal of Cancer 87, 21 27.
45. WHO. (1995) WHO Report on Physical Status. The Use and Interpretation of Anthropometry. WHO technical report seriesnumber 854. WHO, Geneva, Switzerland.
46. Wichmann M.W., Meyer G., Adam M., Höchteln-Vollmar W., Angele M.K., Schalhorn A., Wilkowski R., Müller C. Schildberg F.W. (2003) Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Disease of the Colon and Rectum 46, 875 887.
47. Wu C.W., Chi C.W., Hsieh M.C., Chao M.F., Lui W.Y. P'eng F.K. (1998) Serum tumor necrosis factor in patients with gastric cancer. Anticancer Research 18, 1597 1600.
48. Yeh S.S., Wu S.Y., Levine D.M., Parker T.S., Olsson J.S., Stevens M.R. Schuster M.W. (2001) The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56, M48 M54.
49. Zhou W., Jiang Z., Tian J., Li N. Li J. (2003) Role of NF-κB and cytokine in experimental cancer cachexia. World Journal of Gastroenterology 9, 1567 1570.
50. Zielinski C.C., Mueller C., Tyl E., Tichatschek E., Kubista E. Spona J. (1990) Impaired production of tumor necrosis factor in breast cancer. Cancer 66, 1944 1948.